Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Cash from Investing Activities (2016 - 2025)

Enanta Pharmaceuticals filings provide 14 years of Cash from Investing Activities readings, the most recent being -$47.3 million for Q4 2025.

  • On a quarterly basis, Cash from Investing Activities fell 168.64% to -$47.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$75.9 million, a 154.08% decrease, with the full-year FY2025 number at $40.3 million, down 30.72% from a year prior.
  • Cash from Investing Activities hit -$47.3 million in Q4 2025 for Enanta Pharmaceuticals, down from $2.3 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $72.7 million in Q3 2021 to a low of -$145.7 million in Q2 2023.
  • Median Cash from Investing Activities over the past 5 years was $14.0 million (2022), compared with a mean of $5.4 million.
  • Biggest five-year swings in Cash from Investing Activities: surged 2802.68% in 2021 and later tumbled 998.57% in 2023.
  • Enanta Pharmaceuticals' Cash from Investing Activities stood at $45.5 million in 2021, then dropped by 26.22% to $33.6 million in 2022, then tumbled by 139.07% to -$13.1 million in 2023, then surged by 625.3% to $68.9 million in 2024, then crashed by 168.64% to -$47.3 million in 2025.
  • The last three reported values for Cash from Investing Activities were -$47.3 million (Q4 2025), $2.3 million (Q3 2025), and -$26.5 million (Q2 2025) per Business Quant data.